Back to Authors

Brown, Mary E.

https://orcid.org/0000-0002-2740-9119

Mayo Clinic

University of Minnesota

Citations 1

MET Receptor Tyrosine Kinase Inhibition Reduces Interferon-Gamma (IFN-γ)-Stimulated PD-L1 Expression through the STAT3 Pathway in Melanoma Cells
Song, Kyu Young , Han, Yong Hwan , Roehrich, Heidi , Brown, Mary E. , Torres‐Cabala, Carlos A. , Giubellino, Alessio , Torres-Cabala, Carlos

Cancers | June 30, 2023 | Volume: 15 | Issue: 13 | Pages: 3408

10.3390/cancers15133408 Get It

Melanoma is the leading cause of death from cutaneous malignancy. While targeted therapy and immunotherapy with checkpoint inhibitors have significantly decreased the mortality rate of this disease, advanced melanoma remains a therapeutic challenge. Here, we confirmed that interferon-gamma (IFN-γ)-induced PD-L1 expression in melanoma cell lines. This increased expression was down-regulated by the reduction in phosphorylated STAT3 signaling via MET tyrosine kinase inhibitor treatment. Furthermore, immunoprecipitation and confocal immunofluorescence microscopy analysis reveals MET and PD-L1 protein–protein interaction and colocalization on the cell surface membrane of melanoma cells. Together, these findings demonstrate that the IFN-γ-induced PD-L1 expression in melanoma cells is negatively regulated by MET inhibition through the JAK/STAT3 signaling pathway and establish the colocalization and interaction between an RTK and a checkpoint protein in melanoma cells.